A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Summary
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Have one of the following advanced or metastatic solid tumor cancers: * Non-small cell lung cancer (NSCLC) * Small cell lung cancer (SCLC) * Endometrial cancer * Triple negative breast cancer (TNBC) (characterized by HR-negative disease and HER2-negative expression according to American Society of Clinical Oncology (ASCO) - College of American Pathologists guidelines). * Received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating investigator; OR the individual is refusing the remaining most appropriate stan…
Interventions
- DrugLY4175408
IV infusion
Locations (25)
- Stanford Cancer CenterStanford, California
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research InstituteOrlando, Florida
- Florida Cancer Specialists - SarasotaSarasota, Florida
- The University of Chicago Medical Center (UCMC)Chicago, Illinois
- Community Health NetworkIndianapolis, Indiana
- Massachusetts General HospitalBoston, Massachusetts